Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
r
eports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • Malignant Melanoma: KOL Insight
    Learn More Malignant Melanoma: KOL Insight
    Malignant Melanoma: KOL Insight reveals the impact of immunotherapy on first-line treatment combination choices The arrival of cancer immunotherapy in 2011 significantly changed the landscape for drugs used by...
  • Cancer Immunotherapy: Payer Insight
    Learn More Cancer Immunotherapy: Payer Insight
    Immunotherapies are some of the most promising new weapons in the fight against cancer. But are they promising enough to justify their sky-high prices? Payers aren’t convinced, and say they need better data to make...
  • Multiple Sclerosis: KOL Insight
    Learn More Multiple Sclerosis: KOL Insight
    Roche’s/Biogen’s novel ocrelizumab is set to radically alter the Multiple Sclerosis (MS) treatment paradigm. Which companies and products will lose market share as its use widens and what clinical benefits...
  • Non-Small Cell Lung Cancer: KOL Insight
    Learn More Non-Small Cell Lung Cancer: KOL Insight
    The rapidly evolving non-small cell lung cancer (NSCLC) treatment algorithm is becoming increasingly complex and fragmented. Every advancement brings a new set of questions and concerns. This comprehensive report...
  • Type 2 Diabetes Mellitus: KOL Insight
    Learn More Type 2 Diabetes Mellitus: KOL Insight
    The market for Type 2 Diabetes therapies is extremely crowded. Several classes, including oral and injectable therapies, are all vying for market share. Differentiation remains a critical challenge. What do companies...
  • Psoriasis: KOL Insight (2016)
    Learn More Psoriasis: KOL Insight (2016)
    There is no shortage of effective treatments for psoriasis, and the introduction of novel anti-IL17 and anti-IL23 antibody-based therapies will further expand the treatment options. How will the market develop in the...
  • Idiopathic Pulmonary Fibrosis: KOL Insight
    Learn More Idiopathic Pulmonary Fibrosis: KOL Insight
    Roche’s Esbriet, (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) are the only approved therapies for Idiopathic Pulmonary Fibrosis (IPF). Will either be able to establish themselves as first...
  • Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
    Learn More Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
    Combination therapy is set to take centre stage in the treatment of COPD as leading companies such as GlaxoSmithKline (GSK), Boehringer Ingelheim and AstraZeneca vie for market position and share. But will clinicians,...
  • Nonalcoholic Steatohepatitis: KOL Insight
    Learn More Nonalcoholic Steatohepatitis: KOL Insight
    Why This Report is Essential KOL Views Covered Expect a revolution in the treatment of nonalcoholic steatohepatitis (NASH) as a number of new therapies compete to become the first approved treatment...
  • Ovarian Cancer: KOL Insight
    Learn More Ovarian Cancer: KOL Insight
    Ovarian Cancer: KOL Insight, A new era of targeted therapy provides leading clinician insights on new ovarian cancer (OC) drugs at a time of significant change in the therapy landscape. Why This Report is...
  • Renal Cell Carcinoma: KOL Insight
    Learn More Renal Cell Carcinoma: KOL Insight
    Will new checkpoint inhibitors revive immunotherapy in RCC? Renal Cell Carcinoma: KOL Insight offers opinions of 12 leading US and European KOLs that present business-critical insights for branded pharma and the drug...
  • Ulcerative Colitis: KOL Insight_OLD
    Learn More Ulcerative Colitis: KOL Insight_OLD
    The Ulcerative Colitis (UC) treatment market is already undergoing radical change as new, safer products that slow disease progression have come to market or will be launched in the next few years.  While 5-ASA and...
  • HIV: KOL Insight
    Learn More HIV: KOL Insight
    HIV: KOL Insight examines what frontline clinicians really think about current HIV treatment pathways, addresses the most pressing unmet needs the industry can respond to and gives insight into what's driving long term...
  • Hepatitis C: Payer Insights
    Learn More Hepatitis C: Payer Insights
    The race is on for the company that can competitively price treatment regimens, share data on clinical benefit/positioning and support patient initiatives.  Payer Insights: Hepatitis C, based on in-depth interviews...
  • HIV: KOL Insight  and Consensus Outlook
    Learn More HIV: KOL Insight and Consensus Outlook
    HIV: KOL Insight and Consensus Outlook examines what frontline clinicians really think about current HIV treatment pathways, addresses the most pressing unmet needs the industry can respond to and gives insight into...
  • Diabetes: KOL Insight and Consensus Outlook
    Learn More Diabetes: KOL Insight and Consensus Outlook
    FirstWord’s Therapy Trends: Diabetes offers a complete ongoing analysis of current trends, future forecasts and landscape modifiers. Gain instant access to an accurate, unbiased, qualitative review of the latest...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved